It was shown that targeting EphA2 by the tyrosine kinase inhibitor NVP-BHG712 and its derivatives substantially reduced cell proliferation and induced programmed cell death (apoptosis) in CRC cell lines [15]. This evidence concerns the gene EPHA2 and colorectal carcinoma.